At once a social history and anthropological study of the world's oldest voluntary collective farms, All or None is a story of how landless laborers joined together in Ravenna, Italy to acquire land, sometimes by occupying private land in what they called a "strike in reverse," and how they developed sophisticated land use plans, based not only on the goal of profit, but on the human value of providing work where none was available. It addresses the question of the viability of cooperative enterprise as a potential solution for displaced workers, and as a more humane alternative to capitalist agribusiness
In the late 1960s and early 1970s SHELTER produced a series of campaign pamphlets aimed at raising public awareness of homelessness in the United Kingdom. Back to school from a holiday in the slums! was one such pamphlet which, using a mixture of photographic images and oral testimony, posed a series of questions about the relationship between living in unfit and overcrowded housing and poor educational performance. The school environment was 'a change and a comfort' for children living in slums, but school teachers and social workers were asked if such children had any chance of success as they came each day 'from housing conditions so oppressive that their capacity for education … [was] severely restricted'. On the basis of these interviews SHELTER concluded that their childhood was 'a time of lost opportunity'. Back to school from a holiday in the slums! is used in this article to explore the dialogue between the image and the word and the representation of inequalities.
This article provides a primer on medical device regulations in the United States, Europe, and Canada. Software tools are being developed and shared globally to enhance the accessibility and usefulness of genomic databases. Interactive software tools, such as email or mobile alert systems providing variant classification updates, are opportunities to democratize access to genomic data beyond laboratories and clinicians. Uncertainty over the reliability of outputs, however, raises concerns about potential harms to patients, especially where software is accessible to lay users. Developers may also need to contend with unfamiliar medical device regulations. The application of regulatory controls to genomic software could improve patient and user safety, but could also stifle innovation. Legal uncertainty for developers is compounded where software applications are made available globally (implicating multiple regulatory frameworks), and directly to lay users. Moreover, there is considerable uncertainty over the application of (evolving) medical device regulations in the context of both software and genetics. In this article, criteria and examples are provided to inform determinations of software as medical devices, as well as risk classification. We conclude with strategies for using genomic communication and interpretation software to maximize the availability and usefulness of genetic information, while mitigating the risk of harm to users.
In diesem Artikel werden die Konstruktionen von Identität, Zuhause und Zugehörigkeit von Haitianischen Einwander/innen der ersten und zweiten Generation, welche in Südflorida leben, diskutiert. Die gelebten Erfahrungen der Haitianischen Interviewpartner/innen zeichnen sich durch konfliktgeladene Polaritäten-Erfahrungen aus. In diesem Sinne werden Migrationstheorien der Integration als "Schmelztiegel" oder "Salatschüssel" als nutzlos für das Verständnis der Einwanderungserfahrungen dargestellt. Zudem wird das Konzept der "sozialen Hybridität" wegen dessen Resonanz mit ontologischen Vorstellungen unter Haitianer/innen ausgearbeitet. Dies findet insbesondere in Bezug auf die Push-Pull-Faktoren des Lebens in den Vereinigten Staaten mit verbleibenden Gefühlen für Haiti statt. Das Konzept der gesellschaftlichen Stratifikation hat für viele unserer Haitianischen Gesprächspartner/innen die Wahrnehmung der eigenen Persönlichkeit definiert. In diesem Sinne haben sie "Haitianisch sein" als einzigartig dargestellt, indem sie die Unterschiede zu anderen Afro-stämmigen Erfahrungen, wie zum Beispiel denen von Afro-Amerikaner/innen, beschrieben. Die Analyse der Narrationen zeigt deutlich die Wandlungsfähigkeit ihrer Imagination der Zugehörigkeit und die polyvalenten Bedeutungen, welche mit ihren ambivalenten Identitäten assoziiert sind.
In: Dondorp , W , de Wert , G , Bombard , Y , Bianchi , D W , Bergmann , C , Borry , P , Chitty , L S , Fellmann , F , Forzano , F , Hall , A , Henneman , L , Howard , H C , Lucassen , A , Ormond , K , Peterlin , B , Radojkovic , D , Rogowski , W , Soller , M , Tibben , A , Tranebjærg , L , van El , C G , Cornel , M C & European Society of Human Genetics 2015 , ' Non-invasive prenatal testing for aneuploidy and beyond : challenges of responsible innovation in prenatal screening ' , European Journal of Human Genetics , vol. 23 , no. 11 , pp. 1438-50 . https://doi.org/10.1038/ejhg.2015.57
This paper contains a joint ESHG/ASHG position document with recommendations regarding responsible innovation in prenatal screening with non-invasive prenatal testing (NIPT). By virtue of its greater accuracy and safety with respect to prenatal screening for common autosomal aneuploidies, NIPT has the potential of helping the practice better achieve its aim of facilitating autonomous reproductive choices, provided that balanced pretest information and non-directive counseling are available as part of the screening offer. Depending on the health-care setting, different scenarios for NIPT-based screening for common autosomal aneuploidies are possible. The trade-offs involved in these scenarios should be assessed in light of the aim of screening, the balance of benefits and burdens for pregnant women and their partners and considerations of cost-effectiveness and justice. With improving screening technologies and decreasing costs of sequencing and analysis, it will become possible in the near future to significantly expand the scope of prenatal screening beyond common autosomal aneuploidies. Commercial providers have already begun expanding their tests to include sex-chromosomal abnormalities and microdeletions. However, multiple false positives may undermine the main achievement of NIPT in the context of prenatal screening: the significant reduction of the invasive testing rate. This document argues for a cautious expansion of the scope of prenatal screening to serious congenital and childhood disorders, only following sound validation studies and a comprehensive evaluation of all relevant aspects. A further core message of this document is that in countries where prenatal screening is offered as a public health programme, governments and public health authorities should adopt an active role to ensure the responsible innovation of prenatal screening on the basis of ethical principles. Crucial elements are the quality of the screening process as a whole (including non-laboratory aspects such as information and counseling), education of professionals, systematic evaluation of all aspects of prenatal screening, development of better evaluation tools in the light of the aim of the practice, accountability to all stakeholders including children born from screened pregnancies and persons living with the conditions targeted in prenatal screening and promotion of equity of access.
This paper contains a joint ESHG/ASHG position document with recommendations regarding responsible innovation in prenatal screening with non-invasive prenatal testing (NIPT). By virtue of its greater accuracy and safety with respect to prenatal screening for common autosomal aneuploidies, NIPT has the potential of helping the practice better achieve its aim of facilitating autonomous reproductive choices, provided that balanced pretest information and non-directive counseling are available as part of the screening offer. Depending on the health-care setting, different scenarios for NIPT-based screening for common autosomal aneuploidies are possible. The trade-offs involved in these scenarios should be assessed in light of the aim of screening, the balance of benefits and burdens for pregnant women and their partners and considerations of cost-effectiveness and justice. With improving screening technologies and decreasing costs of sequencing and analysis, it will become possible in the near future to significantly expand the scope of prenatal screening beyond common autosomal aneuploidies. Commercial providers have already begun expanding their tests to include sex-chromosomal abnormalities and microdeletions. However, multiple false positives may undermine the main achievement of NIPT in the context of prenatal screening: the significant reduction of the invasive testing rate. This document argues for a cautious expansion of the scope of prenatal screening to serious congenital and childhood disorders, only following sound validation studies and a comprehensive evaluation of all relevant aspects. A further core message of this document is that in countries where prenatal screening is offered as a public health programme, governments and public health authorities should adopt an active role to ensure the responsible innovation of prenatal screening on the basis of ethical principles. Crucial elements are the quality of the screening process as a whole (including non-laboratory aspects such as information and ...
This paper contains a joint ESHG/ASHG position document with recommendations regarding responsible innovation in prenatal screening with non-invasive prenatal testing (NIPT). By virtue of its greater accuracy and safety with respect to prenatal screening for common autosomal aneuploidies, NIPT has the potential of helping the practice better achieve its aim of facilitating autonomous reproductive choices, provided that balanced pretest information and non-directive counseling are available as part of the screening offer. Depending on the health-care setting, different scenarios for NIPT-based screening for common autosomal aneuploidies are possible. The trade-offs involved in these scenarios should be assessed in light of the aim of screening, the balance of benefits and burdens for pregnant women and their partners and considerations of cost-effectiveness and justice. With improving screening technologies and decreasing costs of sequencing and analysis, it will become possible in the near future to significantly expand the scope of prenatal screening beyond common autosomal aneuploidies. Commercial providers have already begun expanding their tests to include sex-chromosomal abnormalities and microdeletions. However, multiple false positives may undermine the main achievement of NIPT in the context of prenatal screening: the significant reduction of the invasive testing rate. This document argues for a cautious expansion of the scope of prenatal screening to serious congenital and childhood disorders, only following sound validation studies and a comprehensive evaluation of all relevant aspects. A further core message of this document is that in countries where prenatal screening is offered as a public health programme, governments and public health authorities should adopt an active role to ensure the responsible innovation of prenatal screening on the basis of ethical principles. Crucial elements are the quality of the screening process as a whole (including non-laboratory aspects such as information and counseling), education of professionals, systematic evaluation of all aspects of prenatal screening, development of better evaluation tools in the light of the aim of the practice, accountability to all stakeholders including children born from screened pregnancies and persons living with the conditions targeted in prenatal screening and promotion of equity of access.
This paper contains a joint ESHG/ASHG position document with recommendations regarding responsible innovation in prenatal screening with non-invasive prenatal testing (NIPT). By virtue of its greater accuracy and safety with respect to prenatal screening for common autosomal aneuploidies, NIPT has the potential of helping the practice better achieve its aim of facilitating autonomous reproductive choices, provided that balanced pretest information and non-directive counseling are available as part of the screening offer. Depending on the health-care setting, different scenarios for NIPT-based screening for common autosomal aneuploidies are possible. The trade-offs involved in these scenarios should be assessed in light of the aim of screening, the balance of benefits and burdens for pregnant women and their partners and considerations of cost-effectiveness and justice. With improving screening technologies and decreasing costs of sequencing and analysis, it will become possible in the near future to significantly expand the scope of prenatal screening beyond common autosomal aneuploidies. Commercial providers have already begun expanding their tests to include sex-chromosomal abnormalities and microdeletions. However, multiple false positives may undermine the main achievement of NIPT in the context of prenatal screening: the significant reduction of the invasive testing rate. This document argues for a cautious expansion of the scope of prenatal screening to serious congenital and childhood disorders, only following sound validation studies and a comprehensive evaluation of all relevant aspects. A further core message of this document is that in countries where prenatal screening is offered as a public health programme, governments and public health authorities should adopt an active role to ensure the responsible innovation of prenatal screening on the basis of ethical principles. Crucial elements are the quality of the screening process as a whole (including non-laboratory aspects such as information and counseling), education of professionals, systematic evaluation of all aspects of prenatal screening, development of better evaluation tools in the light of the aim of the practice, accountability to all stakeholders including children born from screened pregnancies and persons living with the conditions targeted in prenatal screening and promotion of equity of access.